SELLAS Life Sciences Group, Inc.
NASDAQ:SLS · NASDAQ Capital Market
+$0.31 today
Vol 14.69M · Avg 7.79M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SLS · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$29.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.23, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 -100.0% | $1.0M -86.8% | $7.6M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 -100.0% | $100.0K -50.0% | $200.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 -100.0% | $900.0K -87.8% | $7.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | 90.0% -7.4pp | 97.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $16.0M -16.1% | $19.1M -20.5% | $24.0M -20.7% | $30.3M +41.6% | $21.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $12.3M -1.3% | $12.4M -10.4% | $13.9M +10.2% | $12.6M +11.1% | $11.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $28.3M -10.3% | $31.5M -16.8% | $37.9M -11.6% | $42.9M +31.1% | $32.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $31.5M -16.8% | $37.9M +8186.4% | $457.0K -64.1% | $1.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$26.9M -4350.5% | $632.0K +19.5% | $529.0K +101.7% | -$31.5M -71.9% | -$18.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | -3149.3% -2908.2pp | -241.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$28.3M +10.3% | -$31.5M +16.8% | -$37.9M +9.7% | -$42.0M -65.8% | -$25.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | -4195.0% -3862.2pp | -332.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.4M +123.3% | $632.0K +20.4% | $525.0K +65.6% | $317.0K +5183.3% | $6.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.4M +123.3% | $632.0K +19.5% | $529.0K -18.5% | $649.0K -85.1% | $4.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$26.9M +13.0% | -$30.9M +17.3% | -$37.3M +9.6% | -$41.3M -97.3% | -$20.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | -4130.1% -3854.6pp | -275.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 +100.0% | -$237.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$26.9M +13.0% | -$30.9M +17.3% | -$37.3M +9.6% | -$41.3M -99.5% | -$20.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | -4130.1% -3857.7pp | -272.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +50.0% | -$1 +62.7% | -$1 +37.1% | -$2 -59.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +50.0% | -$1 +62.7% | -$1 +37.1% | -$2 -59.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $109.1M +78.2% | $61.2M +120.3% | $27.8M +43.2% | $19.4M +25.3% | $15.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $109.1M +78.2% | $61.2M +120.3% | $27.8M +43.2% | $19.4M +25.3% | $15.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$332.97M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$330.88M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$260.10M
OmniAb, Inc.
NASDAQ:OABI
$252.47M
Codexis, Inc.
NASDAQ:CDXS
$220.43M
Protara Therapeutics, Inc.
NASDAQ:TARA
$155.32M
MediWound Ltd.
NASDAQ:MDWD
$153.22M
Invivyd, Inc.
NASDAQ:IVVD
$130.22M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$96.78M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SLS generate?
SELLAS Life Sciences Group, Inc. (SLS) reported $0.00 of revenue in fiscal 2025.
Is SLS profitable?
SELLAS Life Sciences Group, Inc. (SLS) reported -$26,863,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.